Publications by authors named "Vered ABitbol"
Background & Aims: Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD). The aim of our study was to evaluate incident cancer rate (recurrence or new-onset cancer) in a cohort of patients with IBD with a history of breast cancer according to the subsequent IBD treatment provided.
Methods: A multicenter retrospective study included consecutive patients with IBD with prior breast cancer.
Article Synopsis
- Biosimilars like CT-P17 offer cost-effective treatment options for patients with inflammatory bowel diseases (IBD) and chronic inflammatory rheumatic diseases (CIRD), but patient beliefs about these treatments can impact their adherence to switching.
- This study involved 232 adult patients who transitioned to CT-P17 from either a low-concentration biosimilar or the reference adalimumab to gauge their treatment satisfaction and experiences over three months.
- Results showed that satisfaction remained stable overall, but significantly more patients switching from a low-concentration biosimilar reported increased satisfaction compared to those switching from the reference product.
Article Synopsis
- A study was conducted with 941 IBD patients to assess their satisfaction with different adalimumab preparations, including biosimilars and the original brand, Humira.
- The average satisfaction rating was 8.5 out of 10, with the highest satisfaction observed for Humira and its biosimilars like Hulio and Amgevita, where scores were notably above 8.5.
- Injection site reactions were reported by 31.8% of patients, and a portion of those previously treated with another adalimumab had discontinued due to side effects; overall, patient satisfaction remained high despite these issues.
Article Synopsis
- Anti-TNFα therapy has transformed the treatment of inflammatory bowel disease (IBD), but it poses a risk for developing active tuberculosis (TB) and potential complications like immune reconstitution inflammatory syndrome (IRIS).
- A French retrospective study analyzed 36 IBD patients with TB treated with anti-TNFα, finding a high incidence of disseminated TB and a significant rate of IRIS, particularly in those with miliary TB.
- Most patients resumed anti-TNFα treatment safely after managing TB, with a favorable overall recovery rate, indicating that restarting this therapy can be an effective approach.
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study.
Clin Gastroenterol Hepatol
December 2024
Background & Aims: The aim of this study was to assess the long-term effectiveness and safety of risankizumab maintenance treatment in a large real-world cohort of patients with Crohn's Disease (CD).
Methods: From May 2021 to August 2023, all consecutive patients with CD treated with risankizumab in 25 GETAID centers have been retrospectively included. The primary endpoint was steroid-free clinical remission (Harvey Bradshaw Index [HBI] <5) at 52 weeks.
Article Synopsis
- The expiration of Humira's patent in 2018 led to the introduction of eight adalimumab biosimilars in Europe and several in the USA, enhancing treatment options for immune and inflammatory conditions.
- While these biosimilars show similar efficacy and safety to Humira, they may have different excipients and device types, complicating treatment decisions for physicians.
- The article aims to help clinicians understand the distinct characteristics of various biosimilars and emphasizes the importance of clear communication with patients to manage expectations and reduce negative reactions.
Background: In recent years, an increasing prevalence of obesity in inflammatory bowel disease (IBD) has been observed. However, only a few studies have focused on the impact of overweight and obesity on IBD-related disability.
Aims: To identify the factors associated with obese and overweight patients with IBD, including IBD-related disability.
Article Synopsis
- Fatigue is a common issue in patients with inflammatory bowel disease (IBD), with 54.1% experiencing fatigue and 37.1% reporting severe fatigue.
- Patients with active IBD experience significantly higher levels of fatigue compared to those with inactive disease.
- Key factors affecting fatigue include age, gender, sick leave, physical pain, emotional well-being, and sleep quality, suggesting that a holistic treatment approach is essential for managing IBD-related fatigue.
Background: The severity of small bowel (SB) inflammation in Crohn's disease (CD) patients is a key component of the therapeutic choice. We aimed to develop a SB-CD Magnetic Resonance Enterography (MRE) index of Inflammation Severity (CDMRIS).
Methods: Each gastroenterologist/radiologist pair in 13 centers selected MREs from 6 patients with SB-CD stratified on their perceived MRE inflammation severity.
Article Synopsis
- The study investigates the effectiveness of adalimumab (ADA) in treating intra-abdominal abscesses in patients with Crohn's disease, specifically those who avoided surgery with prior successful abscess resolution.
- Conducted over two years with 117 eligible patients, the study found that 74% of participants achieved ADA success at 24 weeks, and 72.9% maintained success without relapse or the need for surgery at 104 weeks.
- Key factors linked to ADA failure included previous abscess drainage, longer disease duration, and inflammatory changes in mesenteric fat, highlighting the importance of proper abscess management before starting ADA treatment.
Background: Whether healthcare workers with inflammatory bowel disease (IBD) are at increased risk of Novel coronavirus disease (COVID-19) due to occupational exposure is unknown.
Aim: To assess the risk of COVID-19 in healthcare workers with IBD.
Methods: A case control study enrolled 326 healthcare workers with IBD from 17 GETAID centres and matched non-healthcare workers with IBD controls (1:1) for gender, age, disease subtype and year of diagnosis.
Background: Phase III trials have demonstrated the efficacy of risankizumab in moderate-to-severe Crohn's disease (CD), but no real-world data are currently available. We aimed to assess the short-term effectiveness and safety of risankizumab in patients with CD.
Methods: From May 2021 to May 2022, all patients with refractory luminal CD treated with risankizumab in 22 French GETAID centres were retrospectively included.
Background And Aims: There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care. The primary objective of I-CARE (IBD Cancer and serious infections in Europe) was to assess prospectively safety concerns in IBD, with specific focus on the risk of cancer/lymphoma and serious infections in patients treated with anti-tumor necrosis factor and other biologic monotherapy as well as in combination with immunomodulators.
Methods: I-CARE was designed as a European prospective longitudinal observational multicenter cohort study to include patients with a diagnosis of Crohn's disease, ulcerative colitis, or IBD unclassified established at least 3 months prior to enrollment.
Introduction: There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails.
Methods: We retrieved the full datasets of two observational, multicentre, retrospective studies of patients with UC for whom anti-TNF therapy failed and the patients were then treated with either vedolizumab or ustekinumab. The outcomes included steroid-free clinical remission, clinical remission, treatment persistence, colectomy, hospitalization, and serious and infectious adverse events.
Background: The exact rate of contraindications to anti-TNF therapy and physician perspectives on treatment choices facing to anti-TNF contraindication, are poorly reported.
Methods: A two-week cross-sectional study was conducted in 31 centres. Physicians completed a questionnaire for a total of 1,314 consecutive outpatients with Crohn's disease, assessing each patient's potential contraindications to anti-TNF therapy, the choice of alternative therapy to anti-TNFs, and their preference in an unrestricted reimbursement setting.
Article Synopsis
- - This study focuses on the high risks of venous thromboembolism (VTE) and cardiovascular disease (CVD) in patients with ulcerative colitis (UC) and aims to identify prevalence and risk factors in a large patient population.
- - Conducted in 33 referral centers across France and Belgium, the research involved a questionnaire filled out by 1,071 UC patients to gather self-reported data on their VTE and CVD risk factors, aligning with international guidelines.
- - Findings revealed that over one-third of UC patients reported no cardiovascular risk factors (CVRF), and around 91% had no strong VTE risk factors, suggesting that many patients may have lower risks than anticipated and indicating the need
Article Synopsis
- The study investigates the rare association between IgA vasculitis (IgAV) and inflammatory bowel disease (IBD), primarily in patients treated with anti-TNF-α therapy.
- Out of 43 cases analyzed, the majority showed that IBD, particularly Crohn's disease, preceded the onset of IgAV by an average of 9.2 years, with many patients experiencing purpura and joint issues.
- The findings suggest that discontinuing anti-TNF-α can lead to remission of IgAV, but also raises the risk of IBD flare-ups, while continuing treatment may help manage IBD but lead to recurring IgAV symptoms.
Background: Phase III trials have demonstrated the efficacy and safety of ustekinumab in ulcerative colitis (UC), but few real-life long-term data are currently available.
Aims: To assess the real-world effectiveness and safety of ustekinumab in patients with UC.
Methods: From January to September 2019, all consecutive patients with active UC treated with ustekinumab in a GETAID centre were included.
Reliable diagnostic methods are mandatory for effective management of infection. Histology and culture are the most common invasive methods in current practice, even if molecular methods are gaining in importance. The performance of these conventional methods varies significantly.
View Article and Find Full Text PDFBackground: The burden of inflammatory bowel disease (IBD) is rising worldwide. The goal of IBD treatment is to achieve clinical and endoscopic remission but also prevent disability.
Aims: To identify the predictive factors of disability in a large population of patients with IBD.
Background: There are few data regarding multiple switching from the originator Infliximab to its biosimilars.
Aim: To assess outcomes and patient perspectives in a prospective manner after double switching from Infliximab to the biosimilars CT-P13 and SB2.
Methods: A total of 158 consecutive patients with inflammatory bowel disease (IBD) receiving CT-P13 maintenance therapy were switched to SB2 and followed for 54 weeks.
Background And Aims: Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), and human immunodeficiency virus (HIV) both impact innate and adaptive immunity in the intestinal mucosa. As it is a rare situation, the intersection between HIV and IBD remains unclear, especially the impact of HIV infection on the course of IBD, and the drug safety profile is unknown.
Methods: We conducted a multicenter retrospective cohort study between January 2019 and August 2020.
Background: The prevalence of inflammatory bowel diseases (IBD) is high in women of childbearing age. Achieving clinical remission from conception to delivery using current medications is a major issue in IBD.
Aims: To assess maternal and neonatal complications and management of vedolizumab or ustekinumab) in pregnant women with IBD receiving these agents.
Background And Aim: The inflammatory bowel disease [IBD]-disk is a 10-item self-questionnaire that is used to assess IBD-related disability. The aim of the present study was to evaluate this tool in the assessment of IBD daily-life burden.
Methods: A 1-week cross-sectional study was conducted in 42 centres affiliated in France and Belgium.